361 related articles for article (PubMed ID: 25331003)
1. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
Chang M; Wang J
J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
[TBL] [Abstract][Full Text] [Related]
2. Seamless Phase II/III combination study through response adaptive randomization.
Wang L; Cui L
J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
[TBL] [Abstract][Full Text] [Related]
3. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
Taylor DJ; Grobler A; Abdool Karim SS
Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
[TBL] [Abstract][Full Text] [Related]
4. An adaptive design for phase II non-oncology dose selection clinical trials.
Su Z
Clin Drug Investig; 2010; 30(6):397-403. PubMed ID: 20373828
[TBL] [Abstract][Full Text] [Related]
5. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
Mayo MS; Mahnken JD; Soong SJ
J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
[TBL] [Abstract][Full Text] [Related]
6. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
7. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
9. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
10. A varying-stage adaptive phase II/III clinical trial design.
Dong G
Stat Med; 2014 Apr; 33(8):1272-87. PubMed ID: 24273128
[TBL] [Abstract][Full Text] [Related]
11. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
Sambucini V
J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
[TBL] [Abstract][Full Text] [Related]
12. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
[TBL] [Abstract][Full Text] [Related]
13. A case study of modeling and exposure-response prediction for count data.
Quan H; Mao X; Wei L; Wang L
J Biopharm Stat; 2014; 24(5):1073-90. PubMed ID: 24914574
[TBL] [Abstract][Full Text] [Related]
14. Characterization of dose-response for count data using a generalized MCP-Mod approach in an adaptive dose-ranging trial.
Mercier F; Bornkamp B; Ohlssen D; Wallstroem E
Pharm Stat; 2015; 14(4):359-67. PubMed ID: 26083135
[TBL] [Abstract][Full Text] [Related]
15. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
16. Adaptive sequential testing for multiple comparisons.
Gao P; Liu L; Mehta C
J Biopharm Stat; 2014; 24(5):1035-58. PubMed ID: 24926848
[TBL] [Abstract][Full Text] [Related]
17. Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.
Neven A; Mauer M; Hasan B; Sylvester R; Collette L
J Biopharm Stat; 2020 Mar; 30(2):305-321. PubMed ID: 31331234
[TBL] [Abstract][Full Text] [Related]
18. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
19. Two-stage response adaptive randomization designs for multi-arm trials with binary outcome.
Lu X; Shan G
J Biopharm Stat; 2024 Jul; 34(4):526-538. PubMed ID: 37452825
[TBL] [Abstract][Full Text] [Related]
20. Some drop-the-loser designs for monitoring multiple doses.
Joshua Chen YH; Demets DL; Gordon Lan KK
Stat Med; 2010 Jul; 29(17):1793-807. PubMed ID: 20658548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
